Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted deep sequencing in polycythemia vera and essential thrombocythemia

22 Nov 2016

Abstract excerpt

; combined prevalence was 15% and 15%, respectively. Adverse variants/mutations were associated with inferior survival in both PV (median, 7.7 vs 16.9 years) and ET (median, 9 vs 22 years) and the effect was independent of conventional prognostic models with respective hazard ratio (95% confidence interval) of 2.8 (1.5-5.1) and 2.6 (1.4-4.8); these observations were validated in 215 Italian patients with PV and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29296692
DOI: 10.1182/bloodadvances.2016000216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted deep sequencing in polycythemia vera and essential thrombocythemiaPMID 29296692Read ↗

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.Semantic proximity Read ↗

A molecular signature predicts hematologic evolution in polycythemia vera patients.Semantic proximity Read ↗

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Semantic proximity Read ↗

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.Semantic proximity Read ↗

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients.Semantic proximity Read ↗

Clinical Impact of Next-Generation Sequencing-Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.